SCHEDULE: Prenetics Global Ltd: Stakeholder Ownership Update

Genetel Bioventures Limited and Michael Yang Mengsu report beneficial ownership of 3.3% of Prenetics Global Ltd's Class A Ordinary Shares as of March 31, 2026.

Summary

• This filing is an amendment to a Schedule 13G, indicating a change in beneficial ownership reporting for Prenetics Global Ltd.
• Genetel Bioventures Limited, a Hong Kong private limited company, and Michael Yang Mengsu, its controlling shareholder and a citizen of China (Hong Kong SAR), are the reporting persons.
• As of March 31, 2026, Genetel Bioventures Limited beneficially owns 488,857 Class A Ordinary Shares of Prenetics Global Ltd.
• Michael Yang Mengsu also beneficially owns 488,857 Class A Ordinary Shares, holding sole voting and dispositive power.
• The reported ownership represents 3.3% of the total Class A Ordinary Shares outstanding, based on 14,697,463 shares reported in Prenetics Global Ltd's Form F-3 filed on March 31, 2026.
• The reporting persons certify that the securities were not acquired or held for the purpose of influencing control of the issuer.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it is a routine disclosure of beneficial ownership without new operational or financial information.

Positives

• Reporting persons have clearly disclosed their beneficial ownership, providing transparency to the market.
• The ownership stake of 3.3% is significant enough to warrant reporting under Schedule 13G, indicating a notable interest in the company.

Negatives

• No specific financial performance or operational updates are provided in this filing, limiting insight into the company's current health.

Risks

• The filing does not explicitly mention any risks. However, any significant change in beneficial ownership can sometimes signal shifts in investor sentiment or strategic intentions, which could indirectly pose risks if not aligned with broader market expectations.

Future Outlook

This filing is primarily a disclosure of beneficial ownership and does not contain forward-looking statements or guidance regarding the company's future performance.

Management Comments

• "The filing of this statement should not be construed as an admission that any of the foregoing persons or any Reporting Person is, for the purposes of Section 13 of the Securities Exchange Act of 1934, the beneficial owner of the securities reported herein."
• "By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11."

Industry Context

StockSavvy.ai notes that Schedule 13G filings are standard for institutional investors and significant individual shareholders to report their holdings. This disclosure by Genetel Bioventures Limited and Michael Yang Mengsu indicates a notable, though not controlling, stake in Prenetics Global Ltd, a company operating in the biotechnology or diagnostics sector.

Stakeholder Impact

• Shareholders: Increased transparency regarding significant ownership stakes.
• Management: Awareness of substantial beneficial ownership which may influence future strategic decisions or board composition discussions.

Next Steps

• Continued monitoring of Prenetics Global Ltd's operational and financial performance.
• Observation of any future filings by Genetel Bioventures Limited or Michael Yang Mengsu that might indicate changes in their ownership stake or intentions.

Key Dates

Keywords

Prenetics Global Ltd, Schedule 13G, Beneficial Ownership, Genetel Bioventures Limited, Michael Yang Mengsu, Class A Ordinary Shares, SEC Filing, Ownership Stake